2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107481
    Fasoracetam 110958-19-5 99.41%
    Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD).
    Fasoracetam
  • HY-107620
    PD 198306 212631-61-3 99.75%
    PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.
    PD 198306
  • HY-108439
    Neurodazine 937807-66-4 ≥99.0%
    Neurodazine is a neurogenic inducer, serve as a promoter of neurogenesisin pluripotent cells. Neurodazine promotes neurogenesis by activating Wnt and Shh signaling pathways..
    Neurodazine
  • HY-108497
    L-803087 217480-26-7 ≥98.0%
    L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.
    L-803087
  • HY-109013
    Sofpironium bromide 1628106-94-4 98.26%
    Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes.
    Sofpironium bromide
  • HY-109157
    Ralmitaront 2133417-13-5 99.92%
    Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder.
    Ralmitaront
  • HY-109538
    Secretin (swine) 17034-35-4 99.16%
    Secretin (swine), a neuroendocrine hormone, is the first hormone to be identifie and is secreted by S cells that are localized primarily in the mucosa of the duodenum. Secretin also is a 27-amino acid peptide, which acts on secretin receptors. Secretin is expressed by cells in all mature enteroendocrine cell subsets and can be prompted by fatty acids. Secretin stimulates the secretion of pancreatic water and bicarbonate. Secretin exerts various effects in organs, can be used for the research of digestive system, central nervous system and energy metabolism.
    Secretin (swine)
  • HY-110160
    Pozanicline dihydrochloride 161416-61-1 ≥99.0%
    Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a Ki of 16.7 nM for binding to [3H]cytisine sites. Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a Ki of 17 nM while binding to α7 nAChR is insignificant.
    Pozanicline dihydrochloride
  • HY-110325
    PF-04885614 1480833-70-2
    PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment.
    PF-04885614
  • HY-111474
    Para-aminoblebbistatin 2097734-03-5 99.90%
    Para-aminoblebbistatin is the inhibitor for myosin II. Para-aminoblebbistatin inhibits the ATPase activity of myosin II, thereby blocking the formation and contraction of the actin-myosin network. Para-aminoblebbistatin is a non-fluorescent and photostable Blebbistatin (HY-13813) derivative.
    Para-aminoblebbistatin
  • HY-113421
    Linoleoyl ethanolamide 68171-52-8 ≥98.0%
    Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time.
    Linoleoyl ethanolamide
  • HY-114072
    J-113397 256640-45-6 ≥99.0%
    J-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (Ki: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors.
    J-113397
  • HY-117083
    Clothiapine 2058-52-8 99.93%
    Clothiapine, an atypical antipsychotic agent, shares with clozapine its strong antiserotonergic properties.
    Clothiapine
  • HY-117139
    NESS 0327 494844-07-4 ≥98.0%
    NESS 0327 is a cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor.
    NESS 0327
  • HY-117348
    NCC-149 1316652-41-1 99.14%
    NCC-149 is a selective HDAC8 inhibitor and can be used for neural differentiation research.
    NCC-149
  • HY-117483
    Gly-Pro-Glu 32302-76-4 99.64%
    Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC50 value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .
    Gly-Pro-Glu
  • HY-117541
    Glycyl-glutamine 13115-71-4 ≥98.0%
    Glycyl-glutamine (Glycyl-L-glutamine), as a enzymatic cleavage product of β-endorphin, is apparently an endogenous antagonist of beta-endorphin(1-31) in several systems. Glycyl-glutamine (Glycyl-L-glutamine) is an activate and stable glutamine-containing neuropeptide over glutamine (Gln).
    Glycyl-glutamine
  • HY-117883
    GZ-793A 1356447-90-9 99.50%
    GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction.
    GZ-793A
  • HY-118828
    12-Oxo phytodienoic acid 85551-10-6 ≥99.0%
    12-Oxo phytodienoic acid (12-OPDA) is a plant lipid-derived anti-inflammatory compound. 12-Oxo phytodienoic acid suppresses neuroinflammation by inhibiting Nf-κB and p38 MAPK signaling in Lipopolysaccharides (LPS) (HY-D1056)-activated cells. 12-Oxo phytodienoic acid can be used for neurodegenerative diseases research.
    12-Oxo phytodienoic acid
  • HY-119171
    GSK 366 1953157-39-5 98.17%
    GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor with IC50s of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO), respectively.
    GSK 366
Cat. No. Product Name / Synonyms Application Reactivity